Skip to content
Triangle logo TriangleGet started
← Study library

NCT02511522 · CITED IN SOURCE DOCUMENTS

Study of Palliative Radiotherapy for Symptomatic Hepatocellular Carcinoma and Liver Metastases

An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.

Phase
NA
Status at capture
COMPLETED
Registry last update
2024-10-23

The purpose of this study is to see whether one dose of palliative radiation therapy directed to the liver in combination with standard BSC might help to reduce liver pain/discomfort due to cancer when compared to getting standard BSC alone.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Proportion of Patients Achieving Significant Improvement of Liver Cancer Pain/Discomfort

→

outcome · POSTED

Proportion of Patients Alive at Day 90.

→

outcome · POSTED

Proportion of Patients Achieving a 25% Reduction in Opioid Use at 30 Days (Employing Daily Morphine Equivalence Scale).

→

outcome · POSTED

Proportion of Patients Achieving Improvement of Liver Cancer Pain/Discomfort by ≥ 2 Points in Pain "Intensity at Worst " AND With no Increase in Opioid Use (Employing Daily Morphine Equivalence Scale) on BPI From Baseline to 30 Days.

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * A diagnosis of cancer by at least one criterion listed below: * Pathologically or cytologically proven carcinoma from primary site or site of metastases; * Pathologically or cytologically proven HCC; * HCC diagnosed by standard imaging criteria: arterial enhancement and delayed washout on multiphasic computerized tomography (CT) or magnetic resonance imaging (MRI) in the setting of cirrhosis or chronic hepatitis B or C without cirrhosis. * Largest burden of cancer in the liver is confirmed with CT scan or MRI corresponding to the clinically painful area done within 120 days prior to randomization. * Diffuse (infiltrative involving \> 50% of the liver), multifocal (\> 10 lesions) or locally advanced cancer (at least one lesion \> 10cm, vascular invasion, or multiple lesions with at least one \> 6cm) involving the liver. * In the investigator's opinion, patient is unsuitable for or refractory to standard local and regional therapies. For example: * HCC unsuitable for resection, radiofrequency ablation (RFA), transarterial chemo embolization (TACE) or radical intent, ablative dose stereotactic body radiation therapy (SBRT); * Colorectal carcinoma metastases unsuitable for resection, RFA or radical intent, ablative dose SBRT (e.g. SBRT, \> 30 Gy in 5 fractions, may be an option for up to 3 metastases \< 5cm each, or up to 5 metastases \< 3 cm each). * Unsuitable for, high risk for, or refractory to, standard systemic chemotherapy or targeted therapy (e.g. sorafenib). * Patient reports moderate or severe pain/discomfort prior to the baseline evaluation and this pain is considered "stable" over a period of up to 7 days prior to randomization. Definition of moderate pain: Patient reports level of 4-6 (on a BPI scale from 0 to 10) pain or discomfort "at its worst in the past 24 hours", occurring in the right upper quadrant of the abdomen, the upper abdomen and/or referred to the right shoulder, attributable to liver cancer. Definition of severe pain: Patient reports level of 7-10 (on a BPI scale from 0 to 10) pain or discomfort "at its worst in the past 24 hours", occurring in the right upper quadrant of the abdomen, the upper abdomen and/or referred to the right shoulder, attributable to liver cancer. Definition of "stable" pain: Patient must show moderate or severe "stable" pain by reporting a score of 4 or greater (on 2 separate days within the 7 day period prior to randomization) with the difference of these scores being 0, 1, 2 or 3. * Patient reports moderate or severe pain (i.e. pain score is 4 or higher). This baseline score must also be stable compared to the most recent pre-baseline pain score with the difference between these scores being 0, 1, 2, or 3. * Blood work obtained within 14 days prior to randomization as follows: * Hemoglobin \> 70 g/L; * Platelets \> 25 x 10\^9/L * Absolute neutrophil count (ANC) \> 1.0 x 10\^9/L * INR \< 3; * Bilirubin \< 2.5 UNL (except for subjects with Gilbert's Disease who are eligible despite elevated serum bilirubin level) * AST or ALT \< 10 x ULN. * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-3 within 14 days of Randomization (see Appendix II). * Life expectancy of \> 3 months. * 18 years of age or older at the time of randomization. * Patient is willing to complete the Pre-Baseline Pain/Discomfort Questionnaire and the Pain/Discomfort and Medication Questionnaire in English, French or other validated language (please contact the HE.1 Study Coordinator). The baseline assessment must be completed within required timelines prior to randomization. Unwillingness to complete the Pre-Baseline Pain/Discomfort Questionnaire and Pain/Discomfort and Medication Questionnaire will make the patient ineligible for the study. * Patient is able (i.e. sufficiently fluent) and willing to complete the QoL questionnaires in English, French or other languages in which the FACT-Hep is available. The baseline assessment must be completed within required timelines prior to randomization. Inability (illiteracy in languages listed above, loss of sight, or other equivalent reason) to complete the questionnaires will not make the patient ineligible for the study. However, ability but unwillingness to complete the QoL questionnaires will make the patient ineligible for QoL assessment. * Patient is not pregnant, planning on becoming pregnant or planning on fathering a child in the next 90 days. Women/men of childbearing potential must have agreed to use a highly effective contraceptive method. A woman is considered to be of "childbearing potential" if she has had menses at any time in the preceding 12 consecutive months. In addition to routine contraceptive methods, "effective contraception" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation, or vasectomy/vasectomized partner. However, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures. Women of childbearing potential will have a pregnancy test to determine eligibility as part of the Pre-Study Evaluation; this may include an ultrasound to rule-out pregnancy if a false-positive is suspected. For example, when beta-human chorionic gonadotropin is high and partner is vasectomized, it may be associated with tumour production of hCG, as seen with some cancers. Patient will be considered eligible if an ultrasound is negative for pregnancy * Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each patient must sign a consent form prior to enrolment in the trial to document their willingness to participate; * Patients must be accessible for treatment and follow-up. Investigators must ensure the patients randomized on this trial will be available for complete documentation of the treatment, adverse events, and follow-up. * In accordance with NCIC CTG policy, protocol treatment is to begin within 5 working days of patient randomization (earlier is preferred). Exclusion Criteria: * Prior radiotherapy to the upper abdomen that would result in substantial overlap of the irradiated volume (e.g. \> 50% of liver receiving \> 24 Gy in 2 Gy equivalent dose); * Prior selective internal radiotherapy directed to the liver or hepatic arterial yttrium therapy, at any time. * Cholangitis or acute bacterial infection requiring intravenous antibiotics within 28 days prior to study entry. * Radiographic evidence of intrabiliary cancer within the common or main branches of the biliary system, \< 4 months prior to randomization. * Child-Pugh score greater than C10 (a score of C10 is allowed). * Chemotherapy or TACE administered within the past 4 weeks. * Targeted therapy (e.g. Sorafenib) received within the past 2 weeks. * Plans for chemotherapy, targeted therapy or TACE in the next 4 weeks.
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Patients will be randomized 1:1 to receive best supportive care alone
    intervention Names
    1. Other: Best Supportive Care
    label
    Best Supportive Care
    type
    ACTIVE_COMPARATOR
  2. description
    Patients will be randomized 1:1 to receive best supportive care plus radiation therapy (8 Gy in 1 fraction),
    intervention Names
    1. Other: Best Supportive Care
    2. Radiation: Palliative Radiation Therapy
    label
    Best Supportive Care + RT 8 Gy/1
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Best Supportive Care
    2. Best Supportive Care + RT 8 Gy/1
    description
    Including analgesics, palliative care and/or pain specialist assessment as needed
    name
    Best Supportive Care
    type
    OTHER
  2. arm Group Labels
    1. Best Supportive Care + RT 8 Gy/1
    description
    8 Gy in 1 fraction in whole liver or near whole liver. Including anti-emetic pre-medications
    name
    Palliative Radiation Therapy
    type
    RADIATION
Study design
allocation
RANDOMIZED
intervention Model
PARALLEL
masking Info
masking
NONE
primary Purpose
SUPPORTIVE_CARE
Enrollment
count
66
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    • Proportion of patients achieving improvement of liver cancer pain/discomfort by ≥ 2 points in pain "intensity at worst " on Brief Pain Inventory (BPI) from baseline to day 30.
    measure
    Proportion of Patients Achieving Significant Improvement of Liver Cancer Pain/Discomfort
    time Frame
    30 days
secondary Outcomes
  1. description
    Estimated by Kaplan-Meier method for overall survival defined as time from randomization to death from any cause.
    measure
    Proportion of Patients Alive at Day 90.
    time Frame
    90 days
  2. measure
    Proportion of Patients Achieving a 25% Reduction in Opioid Use at 30 Days (Employing Daily Morphine Equivalence Scale).
    time Frame
    30 days
  3. measure
    Proportion of Patients Achieving Improvement of Liver Cancer Pain/Discomfort by ≥ 2 Points in Pain "Intensity at Worst " AND With no Increase in Opioid Use (Employing Daily Morphine Equivalence Scale) on BPI From Baseline to 30 Days.
    time Frame
    30 days
Full study description
brief Summary
The purpose of this study is to see whether one dose of palliative radiation therapy directed to the liver in combination with standard BSC might help to reduce liver pain/discomfort due to cancer when compared to getting standard BSC alone.
detailed Description
The standard treatment for liver cancer pain or discomfort like yours is known as best supportive care (BSC) and includes pain-relieving medicines called analgesics. This type of treatment can help in some cases; however, some analgesics require a healthy liver to work properly. This means that there are many patients who have a hard time managing their liver cancer pain/discomfort with BSC alone. Sometimes radiation therapy is given in the "palliative" setting meaning it is designed to treat the pain/discomfort and not necessarily to shrink or eliminate the tumour. Palliative radiation therapy is often given when patients have painful bone tumours, but is not yet widely used to treat liver pain/discomfort. Palliative radiation therapy is usually given in smaller amounts and less frequently than other kinds of radiation therapy.
Source references
references
  1. citation
    Dawson LA, Ringash J, Fairchild A, Stos P, Dennis K, Mahmud A, Stuckless TL, Vincent F, Roberge D, Follwell M, Wong RKW, Jonker DJ, Knox JJ, Zimmermann C, Wong P, Barry AS, Gaudet M, Wong RKS, Purdie TG, Tu D, O'Callaghan CJ. Palliative radiotherapy versus best supportive care in patients with painful hepatic cancer (CCTG HE1): a multicentre, open-label, randomised, controlled, phase 3 study. Lancet Oncol. 2024 Oct;25(10):1337-1346. doi: 10.1016/S1470-2045(24)00438-8. Epub 2024 Sep 5.
    pmid
    39245060
    type
    RESULT
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-7ad944f6deaf1f5cd6122126
      edge id
      nct-edge-bae94df9ed0c2fe29144
      requested nct id
      NCT02511522
      primary nct id
      NCT02511522
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source file sha256
      1235a36d17603a47ed3d80a6e33674e87daac9c8bde71462d561cc83457c5468
      payload sha256
      6f386351f9f56c800968ca03e11bd22bccc59e2f169d2f4d1b429a3e35e6ebbd
      payload
      clinical indication matching status
      not_inferred
      end exclusive
      true
      id
      nct-edge-bae94df9ed0c2fe29144
      link basis
      explicit_NCT_identifier_in_acquired_source
      nct id
      NCT02511522
      occurrences
      1. context exact
        ence (radiation therapy for palliation):</p> <div class="pdq-content-list"><ol id="_475"><li>The Canadian Cancer Trials Group <a href="/clinicaltrials/NCT02511522">HE.1</a> trial (NCT02511522), a phase III study published in abstract form, included 66 patients with HCC. Patients were randomly assigned to receive either b
        end
        81817
        exact text
        NCT02511522
        start
        81806
      2. context exact
        alliation):</p> <div class="pdq-content-list"><ol id="_475"><li>The Canadian Cancer Trials Group <a href="/clinicaltrials/NCT02511522">HE.1</a> trial (NCT02511522), a phase III study published in abstract form, included 66 patients with HCC. Patients were randomly assigned to receive either best supportive care alone or
        end
        81846
        exact text
        NCT02511522
        start
        81835
      offset unit
      unicode_code_points
      source file
      /tmp/cancer-full-research/nci/raw/65b6ed083cf16e30e7.html
      source file sha256
      1235a36d17603a47ed3d80a6e33674e87daac9c8bde71462d561cc83457c5468
      source json pointer
      Source null
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source retrieved at
      2026-09-09T23:21:57.902710+00:00
      source string basis
      UTF-8_text_with_universal_newline_translation
      source string sha256
      f65392c282090f79f9724182581fd436e649c37951fc980101dd160f5fec1c6e
      source title
      Primary Liver Cancer Treatment (PDQ®)–Health Professional Version
      source update dates
      1. context
        Updated: April 17, 2025
        datetime
        2025-04-17T12:00:00Z
        display
        April 17, 2025

    Preserved source evidence · Not medical advice